J&J/Millenium Studying Velcade/Rituxan Combo For Treatment Of NHL

Millennium and development partner Johnson & Johnson have initiated a Phase III trial evaluating Velcade (bortezomib) in combination with Genentech/Biogen Idec's Rituxan (rituximab) in the treatment of refractory follicular lymphoma, a subtype of non-Hodgkin's lymphoma, the companies announced April 18